ArticleBreast cancer (Tokyo, Japan)2026
Solamargin-functionalized gold nanoparticles codelivering photothermal-immunotherapy for triple-negative breast cancer.
Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe high rates of metastasis and recurrence in triple-negative breast cancer (TNBC) underscore the limitations of current therapies. Solamargin (SM), a bioactive glycoside, possesses potential antitumor activity, but its efficacy is limited by low potency and off-target effects.
methodsWe engineered Au@PEG-SM, a nanoconjugate designed for targeted delivery. Beyond traditional direct killing, we employed vascular endothelial cell models, STING-specific inhibitors (H-151), and cytokine neutralization assays to rigorously validate the molecular mechanism. Systemic immune profiling, including the analysis of lymph node dendritic cells, and bilateral tumor models were used to assess antitumor efficacy.
resultsAu@PEG-SM synergizes with photothermal therapy (PTT) to achieve a potent 1 plus 1 greater than 2 therapeutic effect. Mechanistically, low-dose SM sensitizes the cGAS-STING pathway in vascular endothelial cells; upon synergistic activation by PTT-released DNA, this triggers a massive secretion of IFN-β and TNF-α, leading to indirect tumor cell apoptosis. This process, combined with robust immunogenic cell death (ICD) and promoted dendritic cell maturation in lymph nodes, triggers a systemic antitumor response. Comprehensive immune profiling revealed that this combination therapy significantly increases the infiltration of NK cells and CD8 + T cells while markedly reducing immunosuppressive MDSCs and regulatory T cells (Tregs) in both primary and distant tumors. When combined with anti-PD-L1 blockade, the therapy eradicated primary tumors and established durable immune memory.
conclusionsThis study establishes Au@PEG-SM as a powerful platform that achieves systemic immune activation via a sensitized STING-secretome-DC cascade. By providing rigorously validated mechanistic insights and a holistic immune landscape, our work offers a promising multimodal paradigm for overcoming TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.